Sublimity to Present at Solebury Trout Virtual Global Healthcare Conference

Solana Beach, CA., May 22, 2020 – Sublimity Therapeutics, a biopharmaceutical company focused on the treatment of ulcerative colitis and GI diseases, today announced that Albert Agro PhD, President and CEO, will present an overview of the company at the upcoming Solebury Trout Virtual Investor Conference. Participant details are as follows:

Date/Time: Tuesday, May 26, 2020, 1:00PM EST
Investor Access:

About Sublimity Therapeutics
Sublimity Therapeutics, a clinical-stage biopharmaceutical company with offices in Dublin, Ireland, and Solana Beach, California, is dedicated to identifying and creating meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. The company’s lead program, ST-0529, an orally delivered topical formulation of cyclosporine for moderate to severe ulcerative colitis, is in Phase 2 clinical development. ST-0529 utilizes Sublimity’s proprietary Single-Multiple Pill (SmPill®) technology, a versatile delivery system for solubilizing active therapeutic agents. This technology has broad applications for drugs with poor solubility, poor gastrointestinal permeability, a propensity for degradation in the stomach and by heat, or suboptimal pharmacokinetics. It also provides an avenue to deliver API directly to the gut with a targeted, local approach. This technology has enabled Sublimity to advance a diverse pipeline of oral small molecules that have the potential to make important contributions to human health. For more information, visit:

Albert Agro
President & CEO
Sublimity Therapeutics
Ph: +1-858-952-2577

Bob Butler
VP Corporate Communications & Strategic Partnerships
Sublimity Therapeutics
Ph: +1-902-240-2250